Home
Playbooks
Confidential Disclosure Agreement (CDA) Playbook for Clinical Research
Confidential disclosure agreement (CDA)

Confidential Disclosure Agreement (CDA) Playbook for Clinical Research

By 
Gavel Team
 |  Written for: 
Sponsor side
 |  Last reviewed: 
November 16, 2026
Run this playbook on your next contract

Gavel Exec reviews and redlines contracts inside Microsoft Word, checked against your own playbook. Start with 25 free queries, no credit card required.

A confidential disclosure agreement (CDA) is the confidentiality contract a clinical trial sponsor, or the contract research organization (CRO) acting for it, signs with a research site so the site can read the protocol and answer a feasibility questionnaire. This playbook gives sponsor-side positions on each CDA term, with the site's usual answer and sample clauses.

Key takeaways

  • Get the institution's authorized signatory on the CDA. At most academic sites a principal investigator's signature alone does not bind the institution.
  • Expect a term of years. Universities commonly cap confidentiality at three to five years, so keep trade secrets out of feasibility packages.
  • Let the site share the protocol with its institutional review board (IRB) and regulators without asking you first; reserve notice for subpoenas and public records requests.
  • Public universities answer to open records laws that a contract cannot override. Mark every page and get a prompt notice promise.
  • Draft the CDA to hand off cleanly to the clinical trial agreement (CTA), and leave publication rights to the CTA.

Last reviewed November 16, 2026. This playbook is general information for lawyers, not legal advice for a specific matter. Gavel publishes it and makes Gavel Exec.

Where the CDA sits in study startup

Sponsors shortlist sites, send a CDA, and release the protocol synopsis, investigator brochure and feasibility questionnaire once it is signed. Mount Sinai's research office tells investigators that "Sponsors will often require an executed CDA in order to release the study protocol."

The CDA covers that evaluation window only. The University of Florida says "A CDA should not be used to cover the actual conduct of research." Conduct, payment, subject injury, data rights and publication belong in the CTA. FDA's investigational drug rules require the sponsor to give each investigator an investigator brochure "Before the investigation begins" (21 C.F.R. 312.55(a)), and the CDA is usually the first contract protecting it.

Advarra's Site-Sponsor Consortium of sponsors, CROs and research sites reports that "delays in CDA execution can delay study startup at a site by weeks or even months" (Consortium industry report). In October 2025 it published a master mutual CDA template (Advarra announcement), and the report encourages sites to accept it without negotiation.

CDA or NDA: what the label changes

Research offices treat the names as one contract type; the University of Florida calls a CDA "also known as a non-disclosure agreement (NDA)." The difference is the counterparty: an institution that answers to IRB review, Food and Drug Administration (FDA) inspection, publication policy and sometimes an open records statute. For standard exclusions and compelled disclosure mechanics, use our NDA playbook for commercial deals. Other types are in the contract playbooks library.

Every preferred position assumes you are a drug, biologic or device sponsor, or its CRO, sending a CDA to a site you hope to activate. You want it signed within days, protecting the protocol and fitting the CTA that follows.

Speed is a sponsor interest too, so several preferred positions are ones sites already accept, such as mutual obligations and silence on governing law.

If you represent the site

Treat the fallback column as your opening position and the escalation column as the points where a sponsor will likely hold firm. Feasibility answers reveal patient volumes and rates, and the Consortium notes that "Bilateral (mutual) CDAs can help eliminate delays at sites that require mutual protection." Hold the term to a fixed number of years and keep the IRB and public records carve-outs.

Site types and sponsor profiles that change the positions

The core table assumes a private academic medical center. These rows show what moves for other sites and sponsors.

Counterparty or sponsor profileWhat changes in the CDAWhy
Public university or state academic medical centerState governing law or silence, no indemnity or arbitration, the public records clause, and the entity name state law assigns.University of Texas System guidance says governing law "Needs to be Texas or silent." The University of Virginia signs as "The Rector and Visitors of the University of Virginia."
Private academic medical center with an affiliated hospitalConfirm whether the university, hospital or practice plan employs the study team, and cover each. Some institutions require a CDA per study.Yale states that "CDAs must be project /study specific."
Independent site or physician practiceYour form usually signs as sent. Make the practice entity the party, and ask which competing studies its coordinators run.With no contracts office, your draft gets little review, and coordinators often run several sponsors' studies.
Site network or site management organization (SMO)One master CDA, a schedule of affiliated sites allowed to receive the protocol, and network responsibility for each.The Consortium report says master CDAs "are efficient precisely because they are broad in coverage."
CRO signing for the sponsorName the sponsor as a party or third-party beneficiary able to enforce, and let the CRO pass feasibility answers to the sponsor.The protocol belongs to the sponsor, which needs a direct right to enforce if the CRO relationship ends.
Publicly traded sponsorA short acknowledgment that study information may be material nonpublic information and that recipients may not trade in your securities while holding it.For insider trading purposes, a duty of trust or confidence exists "Whenever a person agrees to maintain information in confidence," 17 C.F.R. 240.10b5-2(b)(1).

Clinical research CDA positions, clause by clause

Escalate to the clinical contracts lead or in-house counsel, and hold the protocol until the clause is fixed or the study's business lead accepts the risk in writing.

IssuePreferred positionAcceptable fallbackEscalate or walk away ifWhy it matters
Form and directionMutual master CDA covering every study at the institution, on the Site-Sponsor Consortium template or your equivalent.Mutual study-specific CDA where institution policy requires one per protocol.The site offers only a one-way form protecting itself, or wants a new CDA for every amendment.Sites protect feasibility answers and rates too. The Consortium report recommends master mutual CDAs.
Contracting partiesThe entity that employs the investigator and study staff, by its exact legal name.Institution plus its affiliated hospital or practice plan, each responsible for its own personnel.The investigator is a party individually, or the named entity employs none of the study team.A wrong entity leaves the people holding your protocol outside the contract.
Signature and investigator acknowledgmentInstitutional signatory signs; the principal investigator (PI) signs a read and acknowledged line.Institutional signature only, with the institution informing the study team of its duties.Only the PI signs for an institution that bars investigator signatures.Yale, the University of Alabama at Birmingham and Mount Sinai reserve CDA signature to institutional officials.
Scope and permitted useEach study named by compound or device, indication and protocol number, in the CDA or a written study notice under a master CDA. Use only to decide on participation and prepare feasibility, budget and ethics submissions.Master CDA describing your programs in general terms, with each study identified by email.Use for research purposes generally, or for investigator-initiated or competing studies.The University of Florida says a CDA "should typically only allow use of provided information for evaluation purposes."
Definition and markingEverything disclosed about the study in any form, including qualification visit discussions and the study's existence until registration.Marked material, oral disclosures confirmed in writing within 30 days, and unmarked material a reasonable person would treat as confidential.Only marked documents are protected.The fallback follows the Accelerated Confidential Disclosure Agreement (ACDA) form. An applicable clinical trial must register within 21 days after first enrollment, 42 C.F.R. 11.24(a).
Recipients inside the institutionNeed-to-know personnel: investigators, coordinators, research pharmacy, budget and coverage analysis staff.Add committees whose review institution policy requires before participation.Sharing outside the institution without your consent.An academic site's need-to-know group reaches well beyond the study team.
IRB and regulator disclosuresDisclosure to the reviewing institutional review board (IRB) and to the Food and Drug Administration (FDA) or other regulators, without prior notice, marked confidential.Any review body institution policy requires, plus any regulator, with a recipient list on request.Your consent is required before IRB submission, or the CDA limits records FDA may inspect.Drug study investigators must place studies under IRB review, 21 C.F.R. 312.66, and open study records to FDA, 21 C.F.R. 312.68.
Public records requestsNotice within five business days of any request, assertion of each applicable exemption, and time to seek protection before release.Acknowledgment of the state law, with reasonable efforts to notify you before release.A public institution refuses any notice.The Texas Attorney General has ruled that "a governmental body cannot overrule or repeal provisions of the Act through an agreement or contract," OR2020-23631.
Patient informationNo protected health information (PHI) exchanged. Feasibility answers come back as aggregate counts.Patient-level data only under a separate agreement after IRB review.The questionnaire asks for names, birth dates or medical record numbers.The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule allows a review preparatory to research on the researcher's representation that no PHI will be removed, 45 C.F.R. 164.512(i)(1)(ii)(B).
Term and survivalTwo-year disclosure window (three for a master CDA); five years of protection from each disclosure, surviving expiration.Five years from the effective date, or three where policy caps it, with the CTA taking over on signature.Under three years, no survival clause, or an internal demand for perpetual duties.Duke uses three years and accepts up to five. University of Texas System guidance says "3-5 years," seven at most, after termination.
Trade secretsKeep manufacturing, formulation and unpublished chemistry data out. Send the protocol, investigator brochure and questionnaire only.Anything more goes under a separate agreement reviewed by legal.A clinical team plans to send trade secrets under a fixed-term CDA.Harvard's Agreement Terms Quick Guide says Harvard "should never receive" trade secrets.
Publication and academic freedomThe CDA states that no research is conducted under it and that only the later CTA governs publication of results.Institution's clause making confidentiality subject to publication rights in a later CTA.Publication of your information outside a CTA, or sponsor editorial control written into the CDA.University of Texas System guidance says the "PI must always have the right to" publish study results.
Relationship to the CTAOn signature, the CTA's confidentiality terms cover everything disclosed under the CDA.The CDA keeps governing pre-CTA disclosures, with the CTA's survival period.Integration clauses leave pre-CTA disclosures unprotected, or two periods cover one protocol.The ACDA form has an entire agreement clause and does not mention a later CTA.
Return or destructionAfter a written request or notice of non-selection, the site returns or destroys the material within 30 days and confirms it in writing.One secure archival copy, plus records regulation requires, still confidential.Working copies stay in investigators' files after non-selection.IRBs keep research proposals for at least three years after completion, 21 C.F.R. 56.115.
Governing law, indemnity and remediesSilent on governing law and forum; no indemnity; injunctive relief available.The public institution's state law and courts.Arbitration, indemnity or another state's law demanded of a public institution.The Consortium template is silent on governing law for U.S. entities; the University of Virginia is "prohibited from agreeing to binding arbitration."

Who signs: the institution, the investigator and the acknowledgment line

Academic sites route CDAs through a contracts office. Yale states that "Authorized Yale signatories are the only parties authorized to sign CDAs on behalf of Yale University," and the University of Alabama at Birmingham says investigators "are not authorized to sign a CDA on behalf of UAB." Stanford signs trial NDAs through its contract officers but lets researchers sign other NDAs individually, and a researcher who does "becomes personally responsible for managing the protected, confidential information" (Stanford guidance).

An investigator-only signature gives you a claim against one physician and none against the institution holding the files.

Preferred: This Agreement is between Sponsor and Institution. Institution will bind each employee, student and agent who receives Confidential Information to written duties at least as protective as these and is responsible for their breaches. The Principal Investigator signs below only to confirm having read this Agreement and is not a party to it.
Fallback: Before any of its personnel receive Confidential Information, Institution will inform the Principal Investigator and each member of the study team of the obligations in this Agreement and require them to comply.

Institutions resist responsibility for students and volunteers they do not control, so limit it to personnel acting within their roles. University of Texas System guidance has the investigator sign under "I have read this Agreement and understand my obligations hereunder," which sponsors can accept as is.

Term and survival when universities cap confidentiality

Development programs outlast any confidentiality period academic institutions accept. Duke states that "Duke's standard confidentiality term is three (3) years," with up to five if required. The University of Virginia "is unable to agree to indefinite obligations of confidentiality," and UC Berkeley lists a specific end date among the key features of a university CDA.

The Accelerated Confidential Disclosure Agreement, companion to the Accelerated Clinical Trial Agreement that academic medical centers developed with the University-Industry Demonstration Partnership, expires after one year and protects information "for a period of five (5) years from the effective date." Measuring from each disclosure serves a sponsor better when amendments and brochure updates arrive late.

Preferred: Sponsor may disclose Confidential Information under this Agreement for two years after the Effective Date. Institution's obligations for each item of Confidential Information continue for five years after the date Sponsor disclosed it and survive the expiration or termination of this Agreement.
Fallback: Institution's obligations continue for five years after the Effective Date [or three years where Institution's written policy requires] and survive the expiration or termination of this Agreement. If the parties sign a clinical trial agreement for the Study, its confidentiality terms apply to all Confidential Information from its effective date.

Contracts offices want one end date, so accept the effective date as the start when the disclosure window is a year or less, and rely on the CTA for sites you select.

IRB, FDA and other disclosures the site cannot avoid

In a drug study, the investigator must assure that an IRB "will be responsible for the initial and continuing review" of the study (21 C.F.R. 312.66). The IRB keeps "Copies of all research proposals reviewed" for at least three years after the research ends, and FDA may inspect and copy them (21 C.F.R. 56.115). Investigators must also open study records to FDA on request (21 C.F.R. 312.68).

Sites strike any consent requirement for these disclosures, and academic sites run internal committees you should name.

Preferred: Without notice to Sponsor, Institution may disclose Confidential Information, identified as confidential and only as needed, to the ethics committee or institutional review board reviewing the Study, to its scientific review, conflict of interest and research billing committees, and to any regulator with authority over the Study. Any other legally compelled disclosure requires prompt prior written notice where the law permits.
Fallback: Institution may disclose Confidential Information to any committee or board whose review Institution's policies require before it participates in the Study, and to any regulator with authority over the Study. On request, Institution will tell Sponsor which bodies received Confidential Information.

The ACDA form covers disclosure required by "applicable law, IRB, government agency," with prompt notice and only the minimum necessary. That protects you more than the preferred version, so accept it.

Public universities and open records laws

A state university cannot promise more confidentiality than its public records statute allows. In a ruling requested by the University of Texas System, the Texas Attorney General restated that "a governmental body cannot overrule or repeal provisions of the Act through an agreement or contract" (OR2020-23631).

Your protection is procedural. In Texas, when the institution asks the Attorney General for a ruling on a third party's proprietary information, it must make a good faith attempt to notify that party, which may submit reasons until "the 10th business day after the date the person receives the notice" (Texas Government Code 552.305(d)). Without a ruling request, the statute requires no notice.

Florida makes confidential certain proprietary information "received, generated, ascertained, or discovered during the course of research conducted within the state universities" (Fla. Stat. 1004.22(2)). Whether a protocol shared only for a feasibility decision falls inside that exemption is a question for the university's counsel.

Preferred: Sponsor acknowledges that Institution is subject to [State] public records law. If Institution receives a request that may reach Confidential Information, it will notify Sponsor in writing within five business days, assert each exemption it reasonably believes applies, and allow Sponsor to seek protection before any release, to the extent that law permits.
Fallback: Institution's obligations under this Agreement are subject to [State] public records law. Institution will use reasonable efforts to notify Sponsor of any request for Confidential Information before releasing it.

Some institutions will not argue exemptions for a sponsor. Accept notice alone, mark every page proprietary, and assign someone who can respond within the statutory window.

Publication rights and the handoff to the clinical trial agreement

Academic sites guard publication in every research agreement. University of Texas System guidance says the "PI must always have the right to" publish study results. Harvard guidance permits "A maximum of 30 days" for sponsor review plus up to 30 more days of delay for filings, and the University of Virginia says sponsor review "does not include editorial control." Those terms belong in the CTA, since no results exist at the CDA stage.

In the CDA, a publication clause written for results can be read to reach the protocol, and separate integration clauses can leave pre-CTA disclosures under neither agreement.

Preferred: No research will be conducted under this Agreement. The right to publish results of the Study, and Sponsor's right to review proposed publications, will be set out only in any clinical trial agreement the parties sign. When that agreement takes effect, its confidentiality terms will apply to all Confidential Information disclosed under this Agreement for the Study.
Fallback: Nothing in this Agreement limits Institution's right to publish the results of research performed under a later clinical trial agreement in accordance with that agreement. Institution will not publish Sponsor's Confidential Information except as that agreement permits.

Accept a site's policy publication clause when it is tied to results under a later agreement.

Before the CDA goes out for signature

  1. Confirm the contracting entity's exact legal name and that it employs the investigator and coordinators.
  2. Confirm the signatory's authority, and that the investigator signs only an acknowledgment line.
  3. Match the protocol number, compound and indication in the scope to the package you will send.
  4. Pull manufacturing, formulation and other trade secret material out of the feasibility package.
  5. Confirm the feasibility questionnaire asks for counts and no patient identifiers.
  6. Check that disclosures to the IRB, FDA and required committees are permitted.
  7. For a public institution, confirm the public records clause and mark every page proprietary.
  8. Calculate when confidentiality ends and record it in your CDA tracker.
  9. Confirm any publication language points to the CTA.
  10. If the sponsor is publicly traded, check whether your insider trading policy calls for a trading acknowledgment.
  11. Agree on the signing platform and order. The Consortium report states that 21 C.F.R. Part 11 does not apply to CDAs.

Problems that should hold the protocol

  • A principal investigator signing alone for an academic institution.
  • A foundation or practice plan as the party when it does not employ the study team.
  • Confidentiality that ends when the agreement expires.
  • A consent requirement before IRB submission, or any limit on FDA inspection.
  • Patient identifiers in a questionnaire or site response.
  • A publication clause reaching the protocol or investigator brochure.

Loading the CDA positions into Gavel Exec

Gavel Exec is AI contract review and drafting software that works inside Microsoft Word. It generates playbook rules from a checklist, spreadsheet playbook or signed agreements in .docx, Portable Document Format (PDF) or comma-separated values (CSV) form, so a clinical contracts team can start from the table above or from CDAs already signed with its regular sites.

When a site returns its own CDA form, Gavel Exec applies those rules in Word as priority-ranked tracked changes with its reasoning, and lists missing terms such as a public records notice. In the web app, benchmarking labels each provision on-market, off-market or missing. Gavel Exec costs $160 per user per month or $1,740 per user per year, and each user gets 25 free queries with no credit card.

Frequently asked questions

What is a confidential disclosure agreement in clinical research?

It is the contract a sponsor or contract research organization signs with a research site before releasing the protocol and feasibility questionnaire. It protects that information while the site decides whether to take part, and the clinical trial agreement replaces it if the site is selected.

What is the difference between a CDA and an NDA?

They are the same type of contract, and research offices use the names interchangeably. A clinical research CDA is signed by an institution with IRB, FDA, publication and sometimes public records obligations, so it needs carve-outs a commercial NDA lacks.

Why do sponsors require a CDA before sharing the protocol?

The protocol and investigator brochure contain unpublished study design and compound data. A signed CDA puts the site under a written duty of confidence while it reviews feasibility, which is why many sponsors will not release the protocol without one.

Can the principal investigator sign a CDA?

At most academic institutions the investigator has no authority to bind the institution, so an authorized official signs. The investigator usually signs a read and acknowledged line, which confirms awareness of the obligations without making the investigator a party.

How long do confidentiality obligations last in a clinical trial CDA?

Usually a fixed number of years, because many universities will not accept perpetual obligations. Duke's standard is three years with up to five if required, and the Accelerated Confidential Disclosure Agreement form uses five years from the effective date.

Does a CDA cover patient health information?

It should not. At the CDA stage the site reports aggregate patient counts, and HIPAA permits a review of records preparatory to research on the researcher's representation that no protected health information will leave the covered entity.

Related reading: the NDA playbook for confidentiality terms in commercial deals, best practices for building a contract playbook, and using AI to review confidentiality agreements.

Try Gavel Exec free

AI contract review and redlining in Microsoft Word, checked against your own playbook, with the reasoning behind each change.

Start a free trial
25 free queries • No credit card required